Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
Top Cited Papers
Open Access
- 16 October 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (10), 2565-2570
- https://doi.org/10.1002/art.10583
Abstract
Objective Two tumor necrosis factor α (TNFα) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatment of rheumatoid arthritis (RA). Etanercept was licensed in 1998 for treatment of RA and, more recently, for juvenile RA and psoriatic arthritis. Because of potential immunosuppression related to use of anti‐TNFα agents, we sought to identify postlicensure cases of opportunistic infection, including histoplasmosis, in patients treated with these products. Methods The US Food and Drug Administration's (FDA) passive surveillance database for monitoring postlicensure adverse events was reviewed to identify all reports received through July 2001 of histoplasmosis in patients treated with either infliximab or etanercept. Results Ten cases of Histoplasma capsulatum (HC) infection were reported: 9 associated with infliximab and 1 associated with etanercept. In patients treated with infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after the first dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis. Of the 10 patients with histoplasmosis, 9 required treatment in an intensive care unit, and 1 died. All patients had received concomitant immunosuppressive medications in addition to infliximab or etanercept, and all resided in HC‐endemic regions. Conclusion Postlicensure surveillance suggests that acute life‐threatening histoplasmosis may complicate immunotherapy with TNFα antagonists, particularly infliximab. Histoplasmosis should be considered early in the evaluation of patients who reside in HC‐endemic areas in whom infectious complications develop during treatment with infliximab or etanercept.Keywords
This publication has 16 references indexed in Scilit:
- Reactivation of histoplasmosis after treatment with infliximabAmerican Journal Of Medicine, 2002
- Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathwayGastroenterology, 2001
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentThe New England Journal of Medicine, 2001
- The divergent role of tumor necrosis factor receptors in infectious diseasesMicrobes and Infection, 2000
- Disseminated histoplasmosis following prolonged low-dose methotrexate therapyAmerican Journal of Hematology, 1999
- Neutralization of Endogenous Granulocyte-Macrophage Colony-Stimulating Factor Subverts the Protective Immune Response toHistoplasma capsulatumThe Journal of Immunology, 1999
- Complex Requirements for Nascent and Memory Immunity in Pulmonary HistoplasmosisThe Journal of Immunology, 1999
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Opportunistic infection during treatment with low dose methotrexate.American Journal of Respiratory and Critical Care Medicine, 1994
- Immunological aspects of fungal pathogenesisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990